The 2026 Work Plan and Budget of Alzheimer Europe was adopted during the Annual General Meeting on 24 November 2025.

Click here for the 2025 Work Plan.

Alzheimer Europe Core activities

Objective 1: Changing perceptions

In 2026, Alzheimer Europe will

• involve the European Working Group of People affected by Dementia (EWGPWD) and European Dementia Carers Working Group (EDCWG) in its activities and organise two face-to-face meetings of each group and a series of virtual meetings and consultations

• involve the EWGPWD and EDCWG in the organisation of the Annual Conference by including them in the Programme Committee to help with the selection of abstracts

• organise a joint plenary session at the Annual Conference with representatives of both groups

• involve the EWGPWD and EDCWG in various EU projects where AE is asked to provide the views of people with dementia and their carers

• involve the EWGPWD and EDCWG Chairpersons as full voting members at AE Board meetings

• publish recommendations on the recognition of dementia as a disability as seen by people affected by dementia

• identify mechanisms to involve people with dementia and carers from underrepresented groups in Alzheimer Europe’s public involvement activities

• continue its collaboration with the European Disability Forum on the European disability strategy and the implementation of the UN Convention on the Rights of Persons with Disabilities (UNCRPD)

• award, in collaboration with the Alzheimer Europe Foundation and Alzheimer Europe members, a prize for an intergenerational initiative addressing the stigma attached to dementia and changing public perceptions

• continue working with the Council of Europe and contribute to ongoing discussions on legal capacity, guardianship systems and bioethics

Objective 2: Changing policy

In 2026, Alzheimer Europe will

• dedicate its 2026 Dementia in Europe Yearbook to an update on the development of national dementia strategies and their compliance with UNCRPD principles

• coordinate the group of European government experts on dementia and organise two meetings of the group bringing together health ministry officials from at least 20 countries with representatives from the European Commission, the OECD and the World Health Organization

• develop the European Alzheimer’s Alliance and aim to have at least 100 Members of the European Parliament signed up from all Member States of the European Union

• campaign with Members of the European Parliament on the political priorities contained in the Helsinki Manifesto

• organise two lunch debates in the European Parliament in March and September 2026

• actively contribute to and collaborate with JADE, the new EU Joint Action on Dementia

• play an active role on the Patients’ and Consumers’ Working Party of the European Medicines Agency (EMA)

• contribute to the revision of the EMA guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease

• collaborate, as a member, with the European Patients’ Forum, European Disability Forum and European Public Health Alliance and support the development of positions in response to EU policy developments

• identify relevant research developments and communicate them to its member organisations and wider community via its newsletter, social media and website

• involve the organisation’s Expert Advisory Panel in commenting on important research developments and in identifying speakers for its Conference and other meetings

• organise a conference “Sláinte: Building momentum in dementia through policy, research and partnership” in Dublin, Ireland from 27 to 29 October 2026 with the participation of at least 1,000 participants from 40 countries

• collaborate with INTERDEM, the European Alzheimer’s Disease Consortium and the European Academy of Neurology for the organisation of the conference and the selection of topics to be addressed

• evaluate participants’ satisfaction with the conference programme and practical organisation

Objective 3: Changing practices

In 2026, Alzheimer Europe will

• continue to identify phase II and phase III trials on the prevention of Alzheimer’s disease and dementia and include them in the Clinical Trials Watch

• provide information on risk reduction and brain health promotion on the website of Alzheimer Europe

• further develop the public involvement pool by including family members of people with dementia and people at risk of developing dementia

• collaborate with the Brain Health Mission set up by the European Academy of Neurology and contribute to the development and activities of the European Brain Health Partnership

• monitor the introduction of anti-amyloid treatments in European countries, provide comparative information on reimbursement and access policies and support the advocacy efforts of national associations to secure access of people with early AD to these treatments

• collaborate with the European Academy of Neurology on the development of guidelines for the diagnosis and treatment of Alzheimer’s disease

Objective 4: Organisational priorities

In 2026, Alzheimer Europe will

• update its member organisations on relevant EU policy developments and involve them in the development of policy positions through AE’s public affairs meetings

• organise its Alzheimer’s Association Academy as a series of 2 in-person workshops in Brussels (March and September) and 8 online workshops and develop a programme based on the topics identified by its members

• organise an online Annual General Meeting in June for the adoption of the 2025 Annual and Financial Reports and the election of the new Board of Directors (2026-2028) and an in-person members’ meeting in September for the discussion and adoption of the 2027 Annual Report and Budget

• organise quarterly meetings of the AE Board to monitor the association’s financial situation and the implementation of its work plan

Other activities and projects

EU Project participation

In 2026, Alzheimer Europe will

• continue to engage with Horizon Europe, the Innovative Health Initiative, the Joint Programme Neurodegenerative Diseases Research (JPND) and the European Partnership for Personalised Medicine (EP PerMed) to identify opportunities to contribute to and participate in pan-European research projects,

• continue its active involvement in a number of EU funded projects by promoting public involvement activities with people with dementia and their carers in the research consortium, by contributing to ethical and policy discussions and by supporting the communication and dissemination activities towards a non-scientific audience:

  • ACCESS-AD (Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment)
  • AD-RIDDLE (Real world implementation, deployment and validation of early detection tools and lifestyle enhancement)
  • AI-MIND (Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment)
  • AI4Hope (Artificial intelligence cased health, optimism, purpose and endurance in palliative care for dementia)
  • DORIAN GRAY (Devising a personalised risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes)
  • eBRAIN-Health (Actionable Multilevel Health Data)
  • EPND (European Platform for Neurodegenerative Diseases)
  • FIGARO (Finding Alzheimer’s disease progression markers by CSF proteomics)
  • FluiDx-AD (A novel test trio to detect amyloid beta peptides in saliva and blood for enhanced diagnosis and management of Alzheimer’s disease)
  • MultiMeMo (Shorter- and longer-term mechanisms of multimodal interventions to prevent dementia)
  • PREDICTFTD (Accelerating the Validation of Predictive Biomarkers for Frontotemporal Dementia Diagnosis and Subclassification)
  • PREDICTOM (Prediction of Alzheimer’s disease using an AI driven screening platform)
  • PROMINENT (Precision medicine platform in neurodegenerative disease)

• collaborate as an associate partner or sub-contractor in the following research projects

  • HomeDem (Co-designing a Home with Dementia)
  • REBALANCE (Mechanisms of focused ultRasound mEdiated BrAin cLeAniNg Coupled with enhanced mEchanosensation)

Corporate Affairs

In 2026, Alzheimer Europe will

• organise quarterly company round tables bringing together the AE Board, representatives of corporate sponsors and AE member organisations to provide updates on clinical trial developments, on EU and global policy developments and the organisation’s different corporate projects and activities

• continue including phase II and phase III clinical trials, as well as non-drug trials being conducted in Europe on the AE website

• organise an award ceremony for the 2026 anti-stigma award during a networking dinner at the AE Conference in Dublin

• publish three editions of the Dementia in Europe magazine (February, June and October)

• organise two lunch debates in the European Parliament in March and September

• organise a week-long exhibition in the European Parliament from 30 August to 4 September

2026 Calendar

2026 Budget